AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00663351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reflection FSO V Total Hip Replacement
Description: Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
Study NCT02072993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1979
Description: Single dose, oral solution administration
Study NCT02072993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match
Description: Single dose, oral solution administration
Study NCT03536065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid Reduction Intervention
Description: Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
Study NCT03536065 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Care
Description: Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
Study NCT03000751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple Audit Report
Description: The simple audit provides comparison and feedback on radiation doses.
Study NCT03000751 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simple Audit Report
Description: The simple audit provides comparison and feedback on radiation doses.
Study NCT03000751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Component Intervention
Description: The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
Study NCT03000751 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multi-Component Intervention
Description: The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
Study NCT03000751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Meeting
Description: Collaborator meeting with an emphasis on quality improvement.
Study NCT00962455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning & performance feedback
Description: Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
Study NCT00962455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual practice
Description: Usual practice regarding spirometry execution in family practice
Study NCT02245386 — intervention group
Intervention type: RADIATION
Intervention: transperineal pelvic floor ultrasound
Description: Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology.
Study NCT02499536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
Study NCT02552654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Film
Description: Film scene with severe physical and sexual violence.
Study NCT02552654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: 10mg
Study NCT02552654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01016015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT01016015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01016015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT02051283 — intervention group
Intervention type: OTHER
Intervention: RFA
Description: RFA
Study NCT01972984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
Study NCT02470377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
Study NCT02470377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
Study NCT03274661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W
Description: Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
Study NCT00211900 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine
Description: single IM dose totalling 200 mcg of conjugate
Study NCT02425488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing therapeutics education
Description: Educational intervention will focus on~1. Appropriate lifestyles~2. Early recognition of signs/prodromal symptoms of HF~3. Early recognition of signs of inflammation of the ICD-pocket~4. Good management of the device~1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI
Study NCT04679818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine opioid management
Description: Clinical judgement will be according to their standard practice and may include interpretation of blood pressure, heart rate, diaphoresis, tearing, and pupil size. Boluses of fentanyl 1 µg/kg actual body weight (ABW), up to a maximum dose of 100 µg per bolus, can be given per clinical judgement.
Study NCT04679818 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMD-200 Nol-guided opioid administration
Description: PMD-200 Nociception level (NOL) values exceeding 25 for more than 30 seconds will typically be treated with boluses of fentanyl 1µg/kg ABW, up to a maximum of 100 µg per boluses, 5-minute intervals. Towards the end of the surgery (approximately 30-45 minutes before end of surgery, based on clinical judgment), the boluses of fentanyl will be reduced to 0.5 µg/kg ABW, up to a maximum of 50 µg per boluses, 5 minutes intervals. The target of a PMD-200 NOL score below 25 will be maintained until surgery ends
Study NCT01829607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional electrical stimulation of peripheral muscles
Study NCT03475563 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary angioplasty with stent implantation
Description: Coronary angioplasty with BiOSS LIM C stent implantation
Study NCT00689286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BION
Description: They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises.
Study NCT01801605 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS
Description: Active session with stimulation and placebo session with fictive stimulation
Study NCT01801605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Active session with stimulation and placebo session with fictive stimulation
Study NCT02914223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
Study NCT02922660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desflurane
Description: method of anesthesia maintenance with desflurane ranged from 0.5\~1.5 MAC during the procedure
Study NCT02922660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total intravenous anesthesia
Description: method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
Study NCT02922660 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inhalation anesthesia
Description: method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
Study NCT02922660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2-4 μg/ml in TCI
Study NCT02922660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2-4 ng/ml in TCI
Study NCT03450135 — intervention group
Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test
Description: Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
Study NCT03450135 — intervention group
Intervention type: BEHAVIORAL
Intervention: Emotional go/no-go task
Description: Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
Study NCT01968408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: 10(9) CFU/daily
Study NCT01968408 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02477046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tOPV
Description: administered per protocol
Study NCT02477046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV
Description: administered per protocol
Study NCT02477046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: administered per protocol
Study NCT03189433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ryanodex (dantrolene sodium) for injectable suspension
Description: Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
Study NCT00991003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy
Description: The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
Study NCT00991003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Colonoscopy
Study NCT03879577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered to all patients for a minimum of 4 cycles for 12 weeks.
Study NCT03879577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Herceptin
Description: Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
Study NCT03879577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FEC
Description: Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
Study NCT03879577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Description: Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
Study NCT03879577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
Study NCT03879577 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LHRH agonist
Description: Administered to all premenopausal patients.
Study NCT00686218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00686218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given orally
Study NCT00686218 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Testing
Study NCT00686218 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Testing
Study NCT00686218 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Testing
Study NCT00686218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Testing
Study NCT00686218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Testing
Study NCT00686218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Testing
Study NCT01684033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® MPDS
Study NCT01684033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue™ MPS
Study NCT01684033 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lenses
Description: Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
Study NCT02405065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573
Description: BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
Study NCT02687165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran and D-cycloserine
Description: Milnacipran augmented by D-cycloserine
Study NCT02687165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Milnacipran and D-cycloserine
Description: Milnacipran augmented by D-cycloserine
Study NCT03833843 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Description: ECG, Echocardiography and cardiac magnetic resonance imaging
Study NCT00002836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
Study NCT00002836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
Study NCT00002836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
Study NCT00002836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
Study NCT00002836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
Study NCT00002836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
Study NCT00002836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infusion of stem cells on Day 0.
Study NCT03084679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise in treadmill
Description: 30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
Study NCT03084679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Local strengthening exercises
Description: 15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
Study NCT03084679 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stretching exercises
Description: 5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
Study NCT00682435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?
Study NCT00289900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0524A
Study NCT00289900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT00289900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Study NCT03685435 — intervention group
Intervention type: OTHER
Intervention: Bedside ultrasound
Description: Checking for gastric content using bedside ultrasound
Study NCT02516111 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Oral prophylaxis followed by Open flap debridement (OFD)
Study NCT02516111 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OFD with PRF
Description: Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
Study NCT02516111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OFD with ALN
Description: Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
Study NCT02516111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OFD with ATV
Description: Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
Study NCT03607058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinect + Exercise Training
Description: Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
Study NCT03607058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 10 weeks washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
Study NCT00992394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etanercept
Description: etanercept 50 mg once weekly as requested.
Study NCT00992394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: etanercept
Description: etanercept 25 mg or 50 mg as requested.
Study NCT01981993 — intervention group
Intervention type: BIOLOGICAL
Intervention: Urinary proteomic analysis